BIOCRYST PHARMACEUTICALS INC Business Operations Contracts & Agreements
21 Contracts & Agreements
- Agency Agreements (1 contract)
- Development Agreements (17)
- Termination Agreements (2)
- Voting Agreements (1)
- the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,... (Filed With SEC on May 9, 2022)
- the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,... (Filed With SEC on May 9, 2022)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
- Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human... (Filed With SEC on March 12, 2018)
- MUTUAL TERMINATION AND RELEASE AGREEMENT (Filed With SEC on November 30, 2012)
- VOTING AND POST-CLOSING LOCK-UP AGREEMENT (Filed With SEC on October 22, 2012)
- Name TitleWilliam P. Sheridan, M.D. Chief Medical Officer, Principal InvestigatorElliott Berger, Ph.D. Sr. Vice President, Regulatory AffairsWalter G. Gowan, Ph.D. Vice President... (Filed With SEC on March 6, 2009)
- AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 1 2. AMENDMENT/MODIFICATION NO: 3. EFFECTIVE DATE 4. REQUISITION/PURC 5. PROJECT NO. (If... (Filed With SEC on November 10, 2008)
- LICENSE AGREEMENT BETWEEN ALBERT EINSTEIN COLLEGE OF MEDICINE, INDUSTRIAL RESEARCH, LTD AND BIOCRYST PHARMACEUTICALS, INC. Statement 1 1. Definitions 2 1.01 Field 2 1.02 Agreement... (Filed With SEC on November 30, 2005)
- Placement Agency Agreement (Filed With SEC on February 17, 2005)
